10-K · latest 10
What IQVIA's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Major segment restructuring effective Jan 1, 2026, merging business units and renaming segments.
The company is merging its Contract Sales & Medical Solutions into a renamed 'Commercial Solutions' segment and moving Real-World offerings into the R&D segment.
IQVIA invested $1.71B in acquisitions in 2025 to expand its offerings
The company spent $1.714 billion on multiple business acquisitions in 2025 across all three of its reportable segments.
$1.7B
Net investment to acquire businesses in 2025
R&D Solutions backlog grew by $1.6B to $32.7B, with $8.3B expected as revenue in the next year
The Research & Development Solutions segment increased its contracted backlog by $1.6 billion year-over-year, indicating strong sales performance and future revenue visibility.
$1.6B
Year-over-year increase in R&D contracted backlog
The company is actively spending to streamline operations, reduce overcapacity, and integrate acquisitions, with these efforts expected to continue throughout 2026.
$105M
Restructuring costs incurred in 2025
Major segment reorganization effective Jan 1, 2026 creates new 'Commercial Solutions' unit.
IQVIA is merging its Contract Sales & Medical Solutions into the Technology & Analytics Solutions segment, renaming it 'Commercial Solutions'.
IQVIA highlights core challenge of integrating unstructured and siloed healthcare data
The company identifies that critical healthcare information is often unintegrated, unstructured, and siloed in disparate software systems.
AIanalytics
IQVIA targets emerging markets for growth, projecting 5-8% CAGR through 2030
The company identifies pharmaceutical spending in emerging markets as a key growth driver, projecting a 5% to 8% compound annual growth rate through 2030.
6.5%
Projected CAGR for pharmaceutical spending in emerging markets
IQVIA focuses on 'Healthcare-grade AI' as a core pillar of its 'Connected Intelligence' platform
The company is heavily promoting its AI capabilities, branding them as 'Healthcare-grade AI®' and integrating them into its 'IQVIA Connected Intelligence™' platform.
AIadvanced analytics
Identifies a key pain point with unintegrated, unstructured, and siloed data in disparate systems.
The company explicitly acknowledges that despite digitization, critical information remains difficult to use because it's trapped in silos.
AIanalytics
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track IQVIA with the Signal API
One POST /v1/companies/enrich call with iqvia.com returns IQVIA 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"iqvia.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about IQVIA 10-K
When did IQVIA file its latest 10-K?
What does IQVIA's latest 10-K say about restructuring?
Where can I find IQVIA's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .